Last reviewed · How we verify
NCT03939767: XTEND
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
trial testing Aflibercept (Eylea, BAY86-5321) in Wet Age-related Macular Degeneration in 1,563 participants. Completed in 17 October 2023.
7 July 2023
Quick facts
| Lead sponsor | Bayer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,563 |
| Start date | 12 May 2019 |
| Primary completion | 7 July 2023 |
| Estimated completion | 17 October 2023 |
| Sites | 17 locations across Denmark, Colombia, France, Italy, Belgium, Sweden, Ireland, United Kingdom |
Drugs / interventions tested
- Aflibercept (Eylea, BAY86-5321) — full drug profile →
Conditions studied
- Wet Age-related Macular Degeneration — all drugs for Wet Age-related Macular Degeneration →
Sponsor
Bayer — full company profile →
Who can join
50 and older, any sex, with Wet Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD) after decision to treat with Aflibercept (Eylea) was made. Wet AMD is an eye disease that progressively destroys the macula, the central portion of the retina, impairing central vision.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration.
Korobelnik JF, Chaudhary V, Mitchell P, Kang SW, et al · · 2024 · cited 4× · PMID 38198053 · DOI 10.1007/s40123-023-00867-x -
2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohort.
Bailey C, Chandran M, Gale R, Narendran N, et al · · 2025 · cited 1× · PMID 39719502 · DOI 10.1038/s41433-024-03550-y -
Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration: XTEND at 3 Years.
Korobelnik JF, Chaudhary V, Mitchell P, Kang SW, et al · · 2026 · PMID 41269906 · DOI 10.1159/000549663 -
Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration.
Hatz K, Ambresin A, Schmid M, Prünte C, et al · · 2025 · PMID 40217821 · DOI 10.3390/jcm14072370
Verify or expand the search:
- PubMed search for NCT03939767
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Aflibercept (Eylea, BAY86-5321)
Trials testing the same drug.
- NCT06929143 — A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular · active not recruiting
- NCT05705258 — A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels · recruiting
- NCT04519619 — Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG) · recruiting
- NCT03290794 — Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Pat · completed
- NCT03382587 — Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïv · completed
Other recruiting trials for Wet Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT06859515 — A Long-term Follow up Study of EXG102-031 in Participants With wAMD · recruiting
- NCT04645212 — Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] · active not recruiting
- NCT04504123 — MMP-9 Inhibition for Recalcitrant Wet AMD · Phase 2 · recruiting
Other Bayer trials
Trials by the same sponsor.
- NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
- NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
- NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03939767 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bayer
- Last refreshed: 20 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03939767.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing